Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, planetary Phase II objective proceedings evaluating zenocutuzumab successful coagulated tumors affirmative for Neuregulin 1 (NRG1) cistron fusions, reported manageable broadside effects and clinically meaningful efficacy—including a adjacent doubling of progression-free endurance compared with expectations with modular of care—in antecedently treated patients with precocious NRG1-positive cholangiocarcinoma.